Skip to content

Effect of pyridostigmine in post-stroke dysphagia

Evaluation of the therapeutic effect of pyridostigmine in post-stroke dysphagia

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT20210216050383N1
Enrollment
24
Registered
2021-02-21
Start date
2021-02-18
Completion date
Unknown
Last updated
2021-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dysphagia following cerebral infarction. Dysphagia following cerebral infarction

Interventions

Intervention 1: Intervention group:Tablet Pyridostigmine 60 mg TDS before each meals for one month. Intervention 2: Control group: a Placebo tablet one before each meal (three times a day) for one mo

Sponsors

Iran University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients with ischemic stroke revealed by CT scan or MRI 14 to 180 days before intervention and diagnosed to have post-stroke dysphagia according to MASA score(more than 177) and PSR time(more than 1.5 s) assessed by a speech pathologist.

Exclusion criteria

Exclusion criteria: Younger than 18 Hemorrhagic stroke Stroke onset before 14 days or after 180 days Head and/or neck injuries

Design outcomes

Primary

MeasureTime frame
Grade of patients dysphagia according to Mann Assessment of Swallowing Ability score sheet. Timepoint: Measuring the score of Mann Assessment of Swallowing Ability questionnaire in patients at the beginning of the study (before the intervention) and 30 days after the use of pyridostigmine. Method of measurement: Mann Assessment of Swallowing Ability questionnaire.;Pharyngeal swallowing Reflex time. Timepoint: Measurement of pharyngeal swallowing reflex time in patients at the beginning of the study (before the intervention) and 30 days after the use of pyridostigmine. Method of measurement: Assessed by Speech pathologist bedside.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSeyedeh Enssieh Hashemi

Iran University of Medical Sciences

enssieh.hashemi@gmail.com+98 21 2256 3192

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026